234 related articles for article (PubMed ID: 20717823)
1. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
[TBL] [Abstract][Full Text] [Related]
2. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
3. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of 16α-
Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
[TBL] [Abstract][Full Text] [Related]
5. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
[TBL] [Abstract][Full Text] [Related]
6. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
7. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
10. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
Tsujikawa T; Okazawa H; Yoshida Y; Mori T; Kobayashi M; Tsuchida T; Fujibayashi Y
Ann Nucl Med; 2008 Jan; 22(1):73-7. PubMed ID: 18250990
[TBL] [Abstract][Full Text] [Related]
11. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
[TBL] [Abstract][Full Text] [Related]
12. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy and safety of 16α-[
Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
[TBL] [Abstract][Full Text] [Related]
14. Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES.
Tsujikawa T; Yoshida Y; Maeda H; Tsuchida T; Mori T; Kiyono Y; Kimura H; Okazawa H
Br J Radiol; 2012 Jul; 85(1015):1020-4. PubMed ID: 22337690
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.
Yamamoto M; Tsujikawa T; Yamada S; Kurokawa T; Shinagawa A; Chino Y; Mori T; Kiyono Y; Okazawa H; Yoshida Y
Oncotarget; 2017 Apr; 8(14):22581-22589. PubMed ID: 28186981
[TBL] [Abstract][Full Text] [Related]
16. Non-
Kalshetty A; Basu S
PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
[TBL] [Abstract][Full Text] [Related]
17. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
18. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer.
Yoshida Y; Kurokawa T; Sawamura Y; Shinagawa A; Okazawa H; Fujibayashi Y; Kotsuji F
Gynecol Oncol; 2007 Mar; 104(3):764-6. PubMed ID: 17156828
[TBL] [Abstract][Full Text] [Related]
19. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of the Estrogen Receptor β-Selective Radioligand 2-
Antunes IF; van Waarde A; Dierckx RA; de Vries EG; Hospers GA; de Vries EF
J Nucl Med; 2017 Apr; 58(4):554-559. PubMed ID: 27908969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
